November 16, 2017 / 6:45 PM / a month ago

BRIEF-Arbutus’ LNP licensee Alnylam initiates rolling submission of NDA for Patisiran

Nov 16 (Reuters) - Arbutus Biopharma Corp:

* Arbutus’ LNP licensee Alnylam initiates rolling submission of New Drug Application (NDA) to U.S. Food and drug Administration (fda) for Patisiran

* Says Alnylam expects to submit final clinical data for Patisiran by year end ​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below